AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | ||
| Al-Azhar Journal of Pharmaceutical Sciences | ||
| Volume 68, Issue 2, September 2023, Pages 130-158 PDF (1.03 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ajps.2023.332171 | ||
| Authors | ||
| Mostafa Mohammed Aref1; Abeer A Mohamed2; Mohammed A Dahab3; Mohamed Ayman ALy El-Zahabi* 4 | ||
| 1Egyptian Drug Authority (EDA), Giza, Egypt | ||
| 2Egyptian Drug Authority (EDA), Giza, Egypt. Departement of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt. | ||
| 3Departement of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. | ||
| 4Al Mockhaim Al Daem street, Nasr 6thdistrict, Cairo Egypt | ||
| Abstract | ||
| One of the most significant pharmacophoric cores in drug discovery in recent decades, notably in anticancer research, has been the quinoline scaffold. Many lead compounds with promising selective cytotoxic and immunomodulatory properties are discovered using quinoline derivatives. The review of the literature found that quinoline derivatives have the ability to inhibit protein kinases and other molecular targets. It was also designed to be involved in the disruption of tubulin assembly. The purpose of this review is to highlight findings from studies on quinoline compounds that demonstrate several anticancer pathways. Overall, the design, discovery, and development of novel and potential multi-target anticancer agents or drugs may benefit from this class of quinoline molecules. | ||
| Keywords | ||
| Quinoline; Tyrosine kinase; Immunomodulators; Tubulin inhibitors; VEGFR; BCR-Abl; HSP90; Topoisomerases | ||
|
Supplementary Files
|
||
|
Statistics Article View: 761 PDF Download: 2,138 |
||
